{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Nanoliposomal-Irinotecan", "query": { "intervention": "Nanoliposomal-Irinotecan" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 52, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Nanoliposomal-Irinotecan&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-29T19:46:25.175Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04083235", "title": "A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Adenocarcinoma of the Pancreas" ], "interventions": [ { "name": "Irinotecan Liposomal Injection", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "5Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ipsen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 770, "start_date": "2020-02-11", "completion_date": "2025-02-18", "has_results": true, "last_update_posted_date": "2026-04-20", "last_synced_at": "2026-09-29T19:46:25.175Z", "location_count": 72, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 63 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Costa Mesa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04083235" }, { "nct_id": "NCT04731467", "title": "A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor", "Non Small Cell Lung Cancer", "Pancreatic Cancer", "Ovarian Cancer", "Papillary Thyroid Cancer", "Melanoma", "Colorectal Adenocarcinoma" ], "interventions": [ { "name": "CM-24 and Nivolumab - Dose Escalation", "type": "DRUG" }, { "name": "CM-24, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion", "type": "DRUG" }, { "name": "CM-24, Nivolumab, and Nal-IRI/5-FU/LV - Expansion", "type": "DRUG" }, { "name": "Nivolumab, Nab paclitaxel and Gemcitabine - Expansion", "type": "DRUG" }, { "name": "Nivolumab and Nal-IRI/5-FU/LV - Expansion", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Famewave Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 79, "start_date": "2021-03-19", "completion_date": "2024-09-30", "has_results": false, "last_update_posted_date": "2024-12-27", "last_synced_at": "2026-09-29T19:46:25.175Z", "location_count": 5, "location_summary": "Scottsdale, Arizona • Aurora, Colorado • New Haven, Connecticut + 2 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04731467" }, { "nct_id": "NCT03088813", "title": "Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Small Cell Lung Cancer" ], "interventions": [ { "name": "Irinotecan liposome injection", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ipsen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 491, "start_date": "2018-04-25", "completion_date": "2023-07-27", "has_results": true, "last_update_posted_date": "2025-02-19", "last_synced_at": "2026-09-29T19:46:25.175Z", "location_count": 22, "location_summary": "Denver, Colorado • Fort Myers, Florida • St. Petersburg, Florida + 17 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Marietta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03088813" }, { "nct_id": "NCT06483555", "title": "Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Adenocarcinoma", "Metastatic Pancreatic Cancer", "Basal Cell Neoplasm" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Nab paclitaxel", "type": "DRUG" }, { "name": "Erlotinib", "type": "DRUG" }, { "name": "NALIRIFOX", "type": "DRUG" }, { "name": "Folfirinox", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 104, "start_date": "2025-02-06", "completion_date": "2027-08", "has_results": false, "last_update_posted_date": "2026-04-23", "last_synced_at": "2026-09-29T19:46:25.175Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06483555" }, { "nct_id": "NCT06219941", "title": "AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Cancer", "Gastroesophageal Junction Cancer", "Biliary Tract Cancer", "Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "AZD0901", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "l-leucovorin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Nanoliposomal Irinotecan", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 226, "start_date": "2023-12-13", "completion_date": "2027-06-28", "has_results": false, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-09-29T19:46:25.175Z", "location_count": 7, "location_summary": "Orange, California • Palo Alto, California • Santa Rosa, California + 4 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Commack", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06219941" }, { "nct_id": "NCT07340151", "title": "Resection/Synchronous Pulmonary or Hepatic Oligometastatic Pancreatic Ductal Adenocarcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Adenocarcinoma of the Pancreas" ], "interventions": [ { "name": "Surgical resection", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "The University of Texas Health Science Center at San Antonio", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 40, "start_date": "2026-03-02", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-04-14", "last_synced_at": "2026-09-29T19:46:25.175Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07340151" }, { "nct_id": "NCT04753216", "title": "Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Platinum-Resistant Fallopian Tube Carcinoma", "Platinum-Resistant Ovarian Carcinoma", "Platinum-Resistant Primary Peritoneal Carcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma", "Refractory Fallopian Tube Carcinoma", "Refractory Ovarian Carcinoma", "Refractory Primary Peritoneal Carcinoma" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Irinotecan Sucrosofate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 3, "start_date": "2021-03-16", "completion_date": "2021-10-25", "has_results": true, "last_update_posted_date": "2023-01-19", "last_synced_at": "2026-09-29T19:46:25.175Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04753216" }, { "nct_id": "NCT04005339", "title": "NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Biliary Tract Cancer" ], "interventions": [ { "name": "Nanoliposomal Irinotecan", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Georgetown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2019-07-29", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-01-26", "last_synced_at": "2026-09-29T19:46:25.175Z", "location_count": 4, "location_summary": "Washington D.C., District of Columbia • Indianapolis, Indiana • St Louis, Missouri + 1 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04005339" }, { "nct_id": "NCT02022644", "title": "Study of Convection-Enhanced, Image-Assisted Delivery of Liposomal-Irinotecan In Recurrent High Grade Glioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "High Grade Glioma" ], "interventions": [ { "name": "nanoliposomal irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2014-10-23", "completion_date": "2023-05-31", "has_results": false, "last_update_posted_date": "2023-06-29", "last_synced_at": "2026-09-29T19:46:25.175Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02022644" }, { "nct_id": "NCT03368963", "title": "TAS102 in Combination With NAL-IRI in Advanced GI Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Colorectal Adenocarcinoma", "Gastric Adenocarcinoma", "Metastatic Pancreatic Adenocarcinoma", "Non-Resectable Cholangiocarcinoma", "Stage IV Colorectal Cancer", "Stage IV Gastric Cancer", "Stage IV Pancreatic Cancer", "Stage IVA Colorectal Cancer", "Stage IVB Colorectal Cancer", "Stage III Colorectal Cancer", "Stage III Gastric Cancer", "Stage III Pancreatic Cancer", "Unresectable Digestive System Adenocarcinoma", "Unresectable Pancreatic Carcinoma" ], "interventions": [ { "name": "Nanoliposomal Irinotecan", "type": "DRUG" }, { "name": "Trifluridine and Tipiracil Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2018-01-30", "completion_date": "2025-11-28", "has_results": false, "last_update_posted_date": "2025-01-07", "last_synced_at": "2026-09-29T19:46:25.175Z", "location_count": 3, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03368963" } ] }